BioGeneration Ventures
Diede Brunen joined BGV as an Analyst in November 2017 and was promoted to Associate in 2020.
Diede has a broad background in biomedical sciences. He finished the master program Infection & Immunology (cum laude) at Utrecht University in 2012. A major part of his research was performed at The Hospital for Sick Children in Toronto, Canada.
Diede completed his PhD research on mechanisms of cancer drug resistance in the group of Prof. Dr. René Bernards at The Netherlands Cancer Institute in Amsterdam.
BioGeneration Ventures
BioGeneration Ventures (BGV) is a venture capital company, with a focus on early stage European biotech, medtech, and diagnostics companies. BGV has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class teams. The Company manages over €100 million of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together.